rs11571833 - BRCA2

Magnitude 2.8 · 8 studies on file

Reported associations

  • A generalized linear mixed model association tool for biobank-scale data. - Nature genetics (2021) · Jiang L, Zheng Z, Fang H, Yang J · PubMed 34737426

    Compared with linear mixed model-based genome-wide association (GWA) methods, generalized linear mixed model (GLMM)-based methods have better statistical properties when applied to binary traits but are computationally much slower. In the present study, leveraging efficient sparse matrix-based algorithms, we developed a GLMM-based GWA tool, fastGWA-GLMM, that is severalfold to orders of magnitude faster than the state-of-the-art tools when applied to the UK Biobank (UKB) data and scalable to cohorts with millions of individuals. We show by simulation that the fastGWA-GLMM test statistics of both common and rare variants are well calibrated under the null, even for traits with extreme case-control ratios. We applied fastGWA-GLMM to the UKB data of 456,348 individuals, 11,842,647 variants an

  • Cross-cancer genome-wide analysis of lung, ovary, breast, prostate and colorectal cancer reveals novel pleiotropic associations - Unknown journal (n.d.) · Unknown authors · PubMed 27197191

    ABSTRACT: Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-staged approach to conduct genome-wide association studies for lung, ovary, breast, prostate and colorectal cancer from the GAME-ON/GECCO Network (61,851 cases, 61,820 controls) to identify pleiotropic loci. Findings were replicated in independent association studies (55,789 cases, 330,490 controls). We identified a novel pleiotropic association at 1q22 involving breast and lung squamous cell carcinoma, with eQTL analysis showing an association with ADAM15/THBS3 gene expression in lung. We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated wi

  • Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes - Unknown journal (n.d.) · Unknown authors · PubMed 28604730

    ABSTRACT: Summary While several lung cancer susceptibility loci have been identified, much of lung cancer heritability remains unexplained. Here, 14,803 cases and 12,262 controls of European descent were genotyped on the OncoArray and combined with existing data for an aggregated GWAS analysis of lung cancer on 29,266 patients and 56,450 controls. We identified 18 susceptibility loci achieving genome wide significance, including 10 novel loci. The novel loci highlighted the striking heterogeneity in genetic susceptibility across lung cancer histological subtypes, with four loci associated with lung cancer overall and six with lung adenocarcinoma. Gene expression quantitative trait analysis (eQTL) in 1,425 normal lung tissues highlighted RNASET2, SECISBP2L and NRG1 as candidate genes. Other

  • Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer - Unknown journal (n.d.) · Unknown authors · PubMed 27117709

    ABSTRACT: Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 × 10−8) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition,

  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk - Unknown journal (n.d.) · Unknown authors · PubMed 23535729

    ABSTRACT: Breast cancer is the most common cancer among women. Common variants at 27 loci have been identified as associated with susceptibility to breast cancer, and these account for ~9% of the familial risk of the disease. We report here a meta-analysis of 9 genome-wide association studies, including 10,052 breast cancer cases and 12,575 controls of European ancestry, from which we selected 29,807 SNPs for further genotyping. These SNPs were genotyped in 45,290 cases and 41,880 controls of European ancestry from 41 studies in the Breast Cancer Association Consortium (BCAC). The SNPs were genotyped as part of a collaborative genotyping experiment involving four consortia (Collaborative Oncological Gene-environment Study, COGS) and used a custom Illumina iSelect genotyping array, iCOGS, c

  • Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma - Unknown journal (n.d.) · Unknown authors · PubMed 32041948

    ABSTRACT: Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers in the United States. Previous genome-wide association studies (GWAS) have identified 14 single nucleotide polymorphisms (SNPs) associated with cutaneous SCC. Here, we report the largest cutaneous SCC meta-analysis to date, representing six international cohorts and totaling 19,149 SCC cases and 680,049 controls. We discover eight novel loci associated with SCC, confirm all previously associated loci, and perform fine mapping of causal variants. The novel SNPs occur within skin-specific regulatory elements and implicate loci involved in cancer development, immune regulation, and keratinocyte differentiation in SCC susceptibility. The authors perform a meta-analysis of cutaneous squamous cell carcinoma, iden

  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer - Unknown journal (n.d.) · Unknown authors · PubMed 25751625

    ABSTRACT: Genome wide association studies (GWAS) and large scale replication studies have identified common variants in 79 loci associated with breast cancer, explaining ~14% of the familial risk of the disease. To identify new susceptibility loci, we performed a meta-analysis of 11 GWAS comprising of 15,748 breast cancer cases and 18,084 controls, and 46,785 cases and 42,892 controls from 41 studies genotyped on a 200K custom array (iCOGS). Analyses were restricted to women of European ancestry. Genotypes for more than 11M SNPs were generated by imputation using the 1000 Genomes Project reference panel. We identified 15 novel loci associated with breast cancer at P<5×10−8. Combining association analysis with ChIP-Seq data in mammary cell lines and ChIA-PET chromatin interaction data in

  • Association analysis identifies 65 new breast cancer risk loci - Unknown journal (n.d.) · Unknown authors · PubMed 29059683

    ABSTRACT: Breast cancer risk is influenced by rare coding variants in susceptibility genes such as BRCA1 and many common, mainly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. We report results from a genome-wide association study (GWAS) of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry. We identified 65 new loci associated with overall breast cancer at p<5x10-8. The majority of credible risk SNPs in the new loci fall in distal regulatory elements, and by integrating in-silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also fi


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • Genetic counseling and BRCA2 cancer risk management High

    BRCA2 K3326X is a truncating variant affecting multiple DNA repair pathways and increasing risk across several cancer types

    Schedule genetic counseling; discuss screening for ovarian, pancreatic, prostate cancers per NCCN BRCA2 guidelines

Lifestyle

  • Tobacco smoking High

    Active smoking compounds BRCA2 K3326X-related lung cancer risk multiplicatively; impaired DNA repair makes tobacco carcinogens more damaging

    Quit smoking if current; avoid secondhand smoke exposure; discuss cessation aids with physician

  • Sun protection practices Moderate

    BRCA2 K3326X impairs DNA repair responses to UV damage, increasing squamous cell carcinoma risk substantially

    Daily SPF 30+ sunscreen, protective clothing, limit sun exposure 10am-4pm, annual skin checks

Screening

  • Low-dose CT lung cancer screening High

    BRCA2 K3326X truncation impairs homologous recombination DNA repair, substantially increasing lung adenocarcinoma and squamous cell carcinoma risk (OR 1.6-2.5)

    Annual or biennial low-dose CT scan beginning at age 45-50, per oncology consultation

  • Annual skin cancer screening Moderate

    BRCA2 K3326X increases cutaneous squamous cell carcinoma risk through impaired DNA repair response to UV damage

    Annual dermatology examination or monthly skin self-examination with attention to new or changing lesions

  • Breast cancer surveillance Moderate

    BRCA2 K3326X truncation impairs DNA repair and increases breast cancer risk; loss of C-terminal domain reduces protective repair functions

    Discuss with oncologist about MRI surveillance starting age 30, in addition to mammography per NCCN BRCA2 guidelines